Vesey Street Capital Partners (VSCP) announced last week that it completed the full sale of its portfolio company, QualityMetric.
Founded in 1997, QualityMetric combines its proprietary scientifically validated general health and disease-specific surveys with its technology, advanced analytics and sector expertise to work with all the world’s largest pharmaceutical companies in clinical trials and patient surveillance.
VSCP is a strategic private equity manager founded in 2014 that focuses on healthcare services. Since its inception, the firm has consummated 39 transactions across 9 platform businesses and has deployed approximately $600 million in capital.
VSCP had previously acquired QualityMetric in August 2020. Under VSCP’s ownership, QM experienced significant growth and noted platform expansion in real-world evidence and value-based care.
Piper Sandler acted as the exclusive financial advisor to VSCP in this transaction, and Kirkland & Ellis LLP acted as VSCP’s legal advisor. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 22nd clinical trials acquisition of 2023. By comparison, there were 16 clinical trials deals reported between January 1, 2022, and August 22, 2022.
